PVCT.OQBProvectus Biopharmaceuticals, INC

SCHEDULE: Provectus Biopharmaceuticals CEO Boosts Stake to 10.56%

Sentiment:

Amendment to Beneficial Ownership Statement

📋All filings for Provectus Biopharmaceuticals, INC
🔒Login to Follow

Edward Pershing, Chairman and CEO of Provectus Biopharmaceuticals, increased his beneficial ownership to 10.56% through recent convertible note purchases and conversions.

Capital raiseThe Issuer has issued an aggregate of $7,117,500 principal amount of secured convertible promissory notes to the Reporting Person.The Reporting Person purchased multiple convertible promissory notes from the Issuer as part of the "Issuer's 2025 Financing" during October and November 2025, totaling $315,000.The Reporting Person used personal funds, including a personal line of credit, to acquire these securities.

Summary

  • Edward Pershing, Chairman and CEO, now beneficially owns 49,255,894 shares of Provectus Biopharmaceuticals, Inc. common stock, representing 10.56% of the outstanding shares.
  • This ownership includes shares held directly, through retirement plans, stock options, and convertible preferred stock derived from convertible promissory notes.
  • Pershing acquired an aggregate of $7,117,500 principal amount of secured convertible promissory notes from the Issuer between April 13, 2018, and November 26, 2025.
  • Approximately $5,797,500 of these notes, plus interest, converted into 2,244,807 shares of Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share.
  • Pershing also purchased 80,365 shares of Series D-1 Convertible Preferred Stock in a private transaction on November 22, 2024.
  • He currently holds $1,371,033 in convertible notes, which are convertible into 479,047 shares of Series D-1 Convertible Preferred Stock, which are then convertible into 4,790,473 shares of Common Stock.
  • Recent transactions within the last 60 days include purchasing $315,000 in convertible promissory notes from the Issuer's 2025 Financing and the conversion of a $50,000 note into 18,880 shares of Series D-1 Convertible Preferred Stock on October 16, 2025.
  • Personal funds, including a personal line of credit, were used for these acquisitions.

Sentiment

Score: 7

Explanation: The Chairman and CEO's continued and increasing investment in the company through convertible notes and preferred stock conversions signals strong insider confidence. This provides capital to the company, which is positive. However, the ongoing nature of this insider financing and the resulting potential for significant dilution from conversions could be a concern for other shareholders.

Positives

  • Chairman and CEO Edward Pershing continues to demonstrate strong commitment to the company by increasing his beneficial ownership, indicating insider confidence.
  • Significant personal investment by the CEO through the purchase of convertible promissory notes provides capital to the Issuer.

Negatives

  • The continuous issuance of convertible promissory notes to the CEO, and their subsequent conversion, could lead to significant dilution for existing common shareholders.
  • The company appears to be relying on insider financing (the "2025 Financing") which might suggest challenges in securing external institutional funding.

Risks

  • Dilution risk for common shareholders due to the conversion of a substantial amount of preferred stock and convertible notes held by the Reporting Person.
  • Potential for conflicts of interest given the CEO's significant creditor and equity holder position.

Future Outlook

NA

Management Comments

  • "I certify that the information set forth in this statement is true, complete and correct." (Edward Pershing, Chairman and CEO, in the signature block)

Industry Context

This filing primarily concerns insider ownership and financing, not broader industry trends. The reliance on insider financing might suggest challenges for smaller biopharmaceutical companies to raise capital through traditional means, or it could indicate a strong belief in the company's future by its CEO. A detailed industry analysis is not possible from this filing alone.

Related Party Transactions

  • The Issuer has issued an aggregate of $7,117,500 principal amount of secured convertible promissory notes to Edward Pershing, the Chairman and CEO.
  • Edward Pershing purchased multiple convertible promissory notes from the Issuer as part of the "Issuer's 2025 Financing."
  • Edward Pershing purchased 80,365 shares of Series D-1 Convertible Preferred Stock from the Issuer in a private transaction.

Stakeholder Impact

  • Shareholders: Potential for dilution of common stock due to the conversion of preferred stock and convertible notes held by the CEO. However, the CEO's increased stake may also be seen as a positive signal of long-term commitment.
  • Company (Issuer): Benefits from capital infusion through the issuance of convertible notes, supporting operations and potentially reducing immediate cash burn.
  • Creditors: The notes are secured, which provides some protection to the CEO as a creditor.

Next Steps

  • Conversion of the remaining $1,371,033 aggregate principal amount of convertible promissory notes into 479,047 shares of Series D-1 Convertible Preferred Stock, and subsequently into 4,790,473 shares of Common Stock.
  • Potential future transactions related to the "Issuer's 2025 Financing" or other capital needs.

Key Dates

DateDescription
2006Start of period for acquisition of other common stock by Reporting Person.
2016End of period for acquisition of other common stock by Reporting Person.
April 13, 2018Start date for issuance of secured convertible promissory notes to Reporting Person.
November 22, 2024Reporting Person purchased 80,365 shares of Series D-1 Convertible Preferred Stock in a private transaction.
December 6, 2024Filing date of Amendment No. 1 to Schedule 13D.
July 3, 2024Filing date of the Original Schedule 13D.
October 3, 2025Reporting Person purchased a $35,000 convertible promissory note from the Issuer.
October 10, 2025Reporting Person purchased a $60,000 convertible promissory note from the Issuer.
October 16, 2025A $50,000 convertible promissory note held by Reporting Person automatically converted into 18,880 shares of the Issuer's Series D-1 Convertible Preferred Stock; also, end date for conversion of $5,797,500 principal amount of notes into preferred stock.
October 23, 2025Reporting Person purchased a $20,000 convertible promissory note from the Issuer.
October 30, 2025Reporting Person purchased a $65,000 convertible promissory note from the Issuer.
November 6, 2025Reporting Person purchased a $35,000 convertible promissory note from the Issuer.
November 13, 2025Reporting Person purchased a $30,000 convertible promissory note from the Issuer.
November 20, 2025Reporting Person purchased a $30,000 convertible promissory note from the Issuer.
November 26, 2025Reporting Person purchased a $70,000 convertible promissory note from the Issuer; also, the date of event requiring this filing and end date for issuance of secured convertible promissory notes.
December 1, 2025Signature date of the Amendment No. 2 filing.

Recommendation

hold

While the CEO's increased stake signals strong insider confidence and provides necessary capital, the continuous reliance on insider financing and the potential for significant dilution from convertible notes warrant caution. Investors should hold and monitor the company's operational progress and future financing strategies before making further investment decisions.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Schedule 13D, Insider Ownership, Convertible Notes, Series D-1 Preferred Stock, Beneficial Ownership, Biopharmaceuticals, SEC Filing, Corporate Governance, Financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.